Neos Therapeutics brings in $20.6M in funding for extended-release ADHD drugs

Pharmaceutical company Neos Therapeutics, Inc. announced Wednesday that it has completed a round of financing totaling $20.6 million for its late-stage pipeline of innovative extended-release (XR) products for Attention-Deficit Hyperactivity Disorder. The financing included investments by Presidio Partners, Crabtree Partners, CAC LLC, Delaware Street Capital, Burrill Life Sciences Capital Fund III and Essex Capital Corporation, […]

Pharmaceutical company Neos Therapeutics, Inc. announced Wednesday that it has completed a round of financing totaling $20.6 million for its late-stage pipeline of innovative extended-release (XR) products for Attention-Deficit Hyperactivity Disorder.

The financing included investments by Presidio Partners, Crabtree Partners, CAC LLC, Delaware Street Capital, Burrill Life Sciences Capital Fund III and Essex Capital Corporation, according to Business Wire.

Proceeds from this financing will support the Company’s efforts during the FDA review of NT-0102, its methylphenidate XR-ODT drug candidate, as well as the submission of New Drug Applications for two additional potential ADHD drugs – an amphetamine XR-ODT and an amphetamine XR-Liquid Suspension.

The XR products allow for once-daily dosing, and NT-0102 and XR-Liquid eliminate the challenge for young ADHD patients who have difficulty swallowing tablets or capsules.

“We are grateful to our investors for their continued confidence and support of the Company and our management team,” said Vipin K. Garg, Ph.D., President and CEO of Neos. “This places the Company in an excellent financial position as we prepare to transition to a commercial enterprise during the next six to twelve months.”